English Abstract
Journal Article
Add like
Add dislike
Add to saved papers

[Assay of anti-acetylcholine receptor antibodies in myasthenic syndromes of newborn infants].

Eighteen neonates were investigated for antibodies directed against acetylcholine receptors. No antibody was detected in 3 cases of congenital myasthenic syndrome, whereas positive results (3.5 to 250 nM) were obtained in 7 cases of transitory neonatal myasthenia and in 7 of 8 asymptomatic infants born to myasthenic mothers. The neonatal antibodies are fully cleared within 1 to 6 months (half-life: 9 days to 2 and a half months). The prognostic value of the maternal and infantile antibody titers is limited: maternal titer at the end of pregnancy, though usually higher in the mothers of myasthenic children, do not predict or preclude the occurrence of transitory myasthenia, and there is no clear correlation between the severity and duration of the myasthenia and the initial titer or the level of the child's antibodies. The assay which measures antibodies against acetylcholine receptors is useful in that it confirms the diagnosis of transitory myasthenia and excludes congenital myasthenic syndromes.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app